AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated

Artivion benefits from FDA premarket approval of AMDS, removing adoption barriers and unlocking a $1

Artivion secured FDA PMA approval for AMDS, removing IRB hurdles and expanding access for acute aort

Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease

ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular s

ATLANTA, June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular s

Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that A

HERZLIYA, Israel--(BUSINESS WIRE)-- #aortaEd--Endospan, a pioneer in endovascular solutions for comp

ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company fo

Artivion delivers advanced cardiovascular and vascular solutions to healthcare providers worldwide t

MILWAUKEE, May 11, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims

Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript

Artivion NYSE: AORT executives said the company delivered double-digit revenue and adjusted EBITDA g

US stocks traded higher, Nasdaq gained 1.5%. Dow down 0.06%. IT shares up 2.1% while healthcare stoc

Citizens analyst Daniel Stauder maintains Artivion (NYSE:AORT) with a Market Outperform and lower

US stocks rise as Nasdaq gains over 200 points, with tech leading. Nonfarm payrolls beat expectation

Needham analyst Mike Matson maintains Artivion (NYSE:AORT) with a Buy and lowers the price target

Artivion (AORT) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Est

Artivion (NYSE:AORT) lowers FY2026 sales outlook from $486.000 million-$504.000 million to $480.000

Artivion (NYSE:AORT) reported quarterly earnings of $0.08 per share which beat the analyst consensus

First Quarter & Recent Business Highlights: Achieved revenue of $116.3 million in the first quarter

ATLANTA, April 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular

Pressure BioSciences (OTCMKTS:PBIO - Get Free Report) and Artivion (NYSE: AORT - Get Free Report) ar

AORT jumps after FDA approves NEXUS Aortic Arch System, unlocking a potential Endospan acquisition a

Artivion (AORT) witnessed a jump in share price last session on above-average trading volume. The la

Dow Jones falls 250 points as UnitedHealth Group rises on Medicare reimbursement boost, other stocks

Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease

Endospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch dis

SG Americas Securities LLC boosted its position in shares of Artivion, Inc. (NYSE: AORT) by 578.4% i

Artivion, Inc. (NYSE: AORT - Get Free Report)'s stock price gapped down prior to trading on Thursday

Canaccord Genuity analyst William Plovanic maintains Artivion (NYSE:AORT) with a Buy and lowers t

Artivion (NYSE:AORT) reported quarterly earnings of $0.17 per share which beat the analyst consensus

1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low

Canaccord Genuity analyst William Plovanic maintains Artivion (NYSE:AORT) with a Buy and raises t

Citizens analyst Daniel Stauder maintains Artivion (NYSE:AORT) with a Market Outperform and raise

Needham analyst Mike Matson maintains Artivion (NYSE:AORT) with a Buy and raises the price target

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earning